As of May 27
| +0.85 / +1.83%|
The 4 analysts offering 12-month price forecasts for Anika Therapeutics Inc have a median target of 48.50, with a high estimate of 56.00 and a low estimate of 46.00. The median estimate represents a +2.36% increase from the last price of 47.38.
The current consensus among 4 polled investment analysts is to Buy stock in Anika Therapeutics Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.